Detection of cloned TCRD, clonedTCRG, and cloned TCRB gene rearrangements in E2A/HEB-transfected cells as compared with human thymocytes and acute lymphoblastic leukemias
| Rearrangement . | E2A/HEB transfectants . | Thymocytes . | T-ALL, %5-150 . | Precursor B-ALL, %5-150 . | ||||
|---|---|---|---|---|---|---|---|---|
| CD34+ 1a− . | CD34+1a+ . | Total . | CD3− . | TCRγδ+ . | TCRαβ+ . | |||
| TCRD | ||||||||
| Dδ2-Dδ3 | + | ++ | ++ | + | 4 | — | — | 13 |
| Vδ2-Dδ3 | + | + | + | + | 6 | 4 | — | 67 |
| Dδ2-Jδ1 | − | + | ++ | + | 10 | 15 | 7 | — |
| Vδ1-Jδ1 | − | − | + | + | 24 | 56 | 13 | — |
| Vδ2-Jδ1 | − | − | + | + | 10 | 6 | 20 | — |
| Vδ3-Jδ1 | − | − | + | + | 5 | 8 | 7 | — |
| Other | NT | NT | NT | NT | 40 | 10 | 53 | 20 |
| TCRG | ||||||||
| VγI-Jγ1.1/2.1 | − | NT | NT | + | 8 | 9 | 20 | 18 |
| VγII-Jγ1.1/2.1 | − | NT | NT | + | — | — | — | 1 |
| VγIII-Jγ1.1/2.1 | − | NT | NT | + | 1 | — | 1 | — |
| VγIV-Jγ1.1/2.1 | − | NT | NT | + | 1 | 4 | — | 1 |
| VγI-Jγ1.2 | − | NT | NT | + | — | — | — | 1 |
| VγII-Jγ1.2 | − | NT | NT | + | 2 | — | — | — |
| VγIII-Jγ1.2 | NT | NT | NT | + | — | — | — | — |
| VγIV-Jγ1.2 | NT | NT | NT | + | — | — | — | — |
| VγI-Jγ1.3/2.3 | + | − | + | + | 69 | 52 | 58 | 56 |
| VγII-Jγ1.3/2.3 | − | − | + | + | 7 | 24 | 6 | 18 |
| VγIII-Jγ1.3/2.3 | − | − | + | + | 4 | 7 | 9 | — |
| VγIV-Jγ1.3/2.3 | +/− | − | + | + | 4 | 4 | 5 | 5 |
| Other | NT | NT | NT | NT | 4 | 1 | — | — |
| TCRB | ||||||||
| Dβ1-Jβ1 | − | − | + | + | 12 | 16 | 9 | — |
| Dβ1-Jβ2 | − | − | + | + | 4 | 14 | 3 | 16 |
| Dβ2-Jβ2 | − | − | + | + | 11 | 5 | 17 | 17 |
| Vβ-Jβ1 | − | − | − | + | 18 | 13 | 28 | — |
| Vβ-Jβ2 | − | − | − | + | 47 | 45 | 30 | 53 |
| Other | NT | NT | NT | NT | 9 | 7 | 13 | 14 |
| Rearrangement . | E2A/HEB transfectants . | Thymocytes . | T-ALL, %5-150 . | Precursor B-ALL, %5-150 . | ||||
|---|---|---|---|---|---|---|---|---|
| CD34+ 1a− . | CD34+1a+ . | Total . | CD3− . | TCRγδ+ . | TCRαβ+ . | |||
| TCRD | ||||||||
| Dδ2-Dδ3 | + | ++ | ++ | + | 4 | — | — | 13 |
| Vδ2-Dδ3 | + | + | + | + | 6 | 4 | — | 67 |
| Dδ2-Jδ1 | − | + | ++ | + | 10 | 15 | 7 | — |
| Vδ1-Jδ1 | − | − | + | + | 24 | 56 | 13 | — |
| Vδ2-Jδ1 | − | − | + | + | 10 | 6 | 20 | — |
| Vδ3-Jδ1 | − | − | + | + | 5 | 8 | 7 | — |
| Other | NT | NT | NT | NT | 40 | 10 | 53 | 20 |
| TCRG | ||||||||
| VγI-Jγ1.1/2.1 | − | NT | NT | + | 8 | 9 | 20 | 18 |
| VγII-Jγ1.1/2.1 | − | NT | NT | + | — | — | — | 1 |
| VγIII-Jγ1.1/2.1 | − | NT | NT | + | 1 | — | 1 | — |
| VγIV-Jγ1.1/2.1 | − | NT | NT | + | 1 | 4 | — | 1 |
| VγI-Jγ1.2 | − | NT | NT | + | — | — | — | 1 |
| VγII-Jγ1.2 | − | NT | NT | + | 2 | — | — | — |
| VγIII-Jγ1.2 | NT | NT | NT | + | — | — | — | — |
| VγIV-Jγ1.2 | NT | NT | NT | + | — | — | — | — |
| VγI-Jγ1.3/2.3 | + | − | + | + | 69 | 52 | 58 | 56 |
| VγII-Jγ1.3/2.3 | − | − | + | + | 7 | 24 | 6 | 18 |
| VγIII-Jγ1.3/2.3 | − | − | + | + | 4 | 7 | 9 | — |
| VγIV-Jγ1.3/2.3 | +/− | − | + | + | 4 | 4 | 5 | 5 |
| Other | NT | NT | NT | NT | 4 | 1 | — | — |
| TCRB | ||||||||
| Dβ1-Jβ1 | − | − | + | + | 12 | 16 | 9 | — |
| Dβ1-Jβ2 | − | − | + | + | 4 | 14 | 3 | 16 |
| Dβ2-Jβ2 | − | − | + | + | 11 | 5 | 17 | 17 |
| Vβ-Jβ1 | − | − | − | + | 18 | 13 | 28 | — |
| Vβ-Jβ2 | − | − | − | + | 47 | 45 | 30 | 53 |
| Other | NT | NT | NT | NT | 9 | 7 | 13 | 14 |
Data on thymocytes and acute lymphoblastic leukemia compiled from Southern blot and/or polymerase chain reaction data from this study and earlier reports from our laboratory.6,11,44,45 47
T-ALL indicates T-lineage acute lymphoblastic leukemia; B-ALL, B-lineage ALL; TCR, T-cell receptor; TCRD, TCRδ;TCRG, TCRγ; TCRB, TCRβ; NT, not tested.
Frequencies defined as percentage of detectedTCRD rearrangements (on the basis of TCRDJ1 probe hybridization), percentage of detected TCRG rearrangements, and percentage of TCRB rearrangements (involving both the Jβ1 and Jβ2 regions).